文献速递腹部泌尿生殖CTMR

非增强光谱CT与化学位移MRI鉴别乏脂性肾上腺病变

Non-contrast spectral CT vs chemical-shift MRI in discriminating lipid-poor adrenal lesions.
PubMed 文献 · Eur Radiol · 2024-07-10

回顾性纳入110例患者(80个乏脂性腺瘤、30个非腺瘤),比较常规非增强CT、双层光谱CT的ΔHU指数与化学位移MRI信号强度指数(SI-index)的诊断效能。ΔHU指数AUC 0.919,优于常规CT的0.791,与SI-index的0.952相近;对≤25 HU腺瘤两者敏感度均为96.0%,对>25 HU腺瘤SI-index敏感度更高。

要点

  • 乏脂性腺瘤ΔHU指数(148.0±103.2)显著高于非腺瘤(19.4±25.8),常规CT衰减则较低。
  • ΔHU指数AUC 0.919,优于常规非增强CT的0.791,与SI-index的0.952无显著差异。
  • 对≤25 HU腺瘤,ΔHU指数与SI-index敏感度均达96.0%(48/50)。

核心结论

  • 非增强光谱CT与化学位移MRI鉴别乏脂性腺瘤均优于常规非增强CT;对>25 HU腺瘤CS-MRI敏感度更高,对≤25 HU腺瘤光谱CT具有较高鉴别价值,可能作为CS-MRI的替代并避免对不确定肾上腺偶发瘤的额外检查。

研究设计与样本

  • 回顾性研究,纳入110例患者(69男、41女,平均年龄66.5±13.4岁),共80个乏脂性腺瘤和30个非腺瘤,均行非增强双层光谱CT和化学位移MRI。

关键影像表现/征象

  • 乏脂性腺瘤常规非增强CT衰减为22.4±8.6 HU,低于非腺瘤的32.8±48.5 HU。
  • 乏脂性腺瘤ΔHU指数为148.0±103.2,高于非腺瘤的19.4±25.8。
  • 乏脂性腺瘤SI-index为41.6±19.6,高于非腺瘤的4.2±10.2。

诊断标准与关键数值

  • ΔHU指数计算公式为(虚拟单能140 keV与40 keV图像衰减差)/常规衰减×100。
  • 在达到>95%特异度时,ΔHU指数诊断腺瘤的AUC为0.919(95%CI 0.852-0.963),敏感度75.0%(60/80)。
  • 常规非增强CT衰减诊断腺瘤的AUC为0.791(95%CI 0.703-0.863),敏感度27.5%(22/80)。
  • SI-index诊断腺瘤的AUC为0.952(95%CI 0.894-0.984),敏感度85.0%(68/80)。
  • 对≤25 HU腺瘤,ΔHU指数与SI-index敏感度均为96.0%(48/50);对>25 HU腺瘤,SI-index敏感度66.7%(20/30),ΔHU指数为40.0%(12/30)。

临床应用与阅片要点

  • 对非增强CT上>10 HU的乏脂性肾上腺病变,可计算ΔHU指数辅助鉴别腺瘤与非腺瘤。
  • 对≤25 HU的病变,光谱CTΔHU指数敏感度高,可能避免额外检查。
  • 对>25 HU的病变,化学位移MRI的SI-index敏感度优于ΔHU指数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare the diagnostic performance of conventional non-contrast CT, dual-energy spectral CT, and chemical-shift MRI (CS-MRI) in discriminating lipid-poor adenomas (> 10-HU on non-contrast CT) from non-adenomas.

METHODS: A total of 110 patients (69 men; 41 women; mean age 66.5 ± 13.4 years) with 80 lipid-poor adenomas and 30 non-adenomas who underwent non-contrast dual-layer spectral CT and CS-MRI were retrospectively identified. For each lesion, non-contrast attenuation on conventional 120-kVp images, ΔHU-index ([attenuation difference between virtual monoenergetic 140-keV and 40-keV images]/conventional attenuation × 100), and signal intensity index (SI-index) were quantified. Each parameter was compared between adenomas and non-adenomas using the Mann-Whitney U-test. The area under the receiver operating characteristic curve (AUC) and sensitivity to achieve > 95% specificity for adenoma diagnosis were determined.

RESULTS: Conventional non-contrast attenuation was lower in adenomas than in non-adenomas (22.4 ± 8.6 HU vs 32.8 ± 48.5 HU), whereas ΔHU-index (148.0 ± 103.2 vs 19.4 ± 25.8) and SI-index (41.6 ± 19.6 vs 4.2 ± 10.2) were higher in adenomas (all, p < 0.001). ΔHU-index showed superior performance to conventional non-contrast attenuation (AUC: 0.919 [95% CI: 0.852-0.963] vs 0.791 [95% CI: 0.703-0.863]; sensitivity: 75.0% [60/80] vs 27.5% [22/80], both p < 0.001), and near equivalent to SI-index (AUC: 0.952 [95% CI: 0.894-0.984], sensitivity 85.0% [68/80], both p > 0.05). Both the ΔHU-index and SI-index provided a sensitivity of 96.0% (48/50) for hypoattenuating adenomas (≤ 25 HU). For hyperattenuating (> 25 HU) adenomas, SI-index showed higher sensitivity than ΔHU-index (66.7% [20/30] vs 40.0% [12/30], p = 0.022).

CONCLUSIONS: Non-contrast spectral CT and CS-MRI outperformed conventional non-contrast CT in distinguishing lipid-poor adenomas from non-adenomas. While CS-MRI demonstrated superior sensitivity for adenomas measuring > 25 HU, non-contrast spectral CT provided high discriminative values for adenomas measuring ≤ 25 HU.

CLINICAL RELEVANCE STATEMENT: Spectral attenuation analysis improves the diagnostic performance of non-contrast CT in discriminating lipid-poor adrenal adenomas, potentially serving as an alternative to CS-MRI and obviating the necessity for additional diagnostic workup in indeterminate adrenal incidentalomas, particularly for lesions measuring ≤ 25 HU.

KEY POINTS: Incidental adrenal lesion detection has increased as abdominal CT use has become more frequent. Non-contrast spectral CT and CS-MRI differentiated lipid-poor adenomas from non-adenomas better than conventional non-contrast CT. For lesions measuring ≤ 25 HU, spectral CT may obviate the need for additional evaluation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Nagayama Y, Uchimura R, Maruyama N, et al. Non-contrast spectral CT vs chemical-shift MRI in discriminating lipid-poor adrenal lesions. Eur Radiol. 2024. PMID: 38985184. doi:10.1007/s00330-024-10929-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。